First-Line Medications for Osteoporosis

First-Line Medications for Osteoporosis


Identification: MSNJ1918
Issue: November-December 2019
Volume: Vol. 28/No. 6
Credits (Post Test and/or Evaluation Required)
Available until 12/31/2021
  • 1.30 - CH

Non-member: $20.00

Description

Contact hours available until 12/31/21.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Authors Conflict of Interest Disclosure:

The author(s), editor, editorial committee, content reviewers, and education director reported no actual or potential conflict of interest in relation to this continuing nursing education article.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
This session is jointly provided by Anthony J. Jannetti, Inc. (AJJ) and the Academy of Medical-Surgical Nurses (AMSN).

Anthony J Jannetti, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Anthony J. Jannetti, Inc. is an approved provider of continuing nursing education by the California Board of Registered Nurses, Provider Number CEP 5387.

This article was reviewed and formatted for contact hour credit by Michele Boyd, MSN, RN, AMSN Education Director.

Learning Outcome:

After completing this learning activity, the learner will be able to discuss the latest evidence regarding first-line medication treatment for osteoporosis and the implications for nursing care and patient education.

Learning Engagement Activity:

Review the Screening and Diagnosis section of the article. What is the common underlying recommendation for osteoporosis screening?

Author(s)

Credits Available


First-Line Medications for Osteoporosis

You must be logged in and own this product in order to post comments.

Floremil Aruejo
12/24/19 11:50 am

Very informative

Mary Pries
1/3/20 2:36 pm

good article informative

Nicole Jones
1/19/20 7:07 pm

Delirium is defined as an acute impairment in global cognitive function, develops over a short period of time hours to days. Sometimes, this cognitive impairment fluctuates during the course of the day. Decompensation of cerebral function in response to one or more decompensation pathophysiology stresses can occur during the time of illness. Article was interesting and gained a lot of knowledge from it.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content